$ADAPY

$0.03 +$0.00 (3.08%) Close

$ADAPY Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 1.59B shares outstanding

Who owns ADAPY?

By type of holder

Institutions 0.0% Insiders 0.0% Everyone else 100.0%

Concentration Top 10 holders own 0.0%

New Enterprise Associates 14, L.P. 0.0% · NEA Partners 14, L.P. 0.0%

Institutional ownership

0.0%

0.0 pts vs last qtr

Institutional holders

-1 vs last qtr

Net shares bought

−3.7K

by institutions in Q2 2026

New / sold out

0 / 1

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

None.

Biggest sellers in Q2 2026

Rhumbline Advisers SOLD OUT −3.7K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Adaptimmune Therapeutics PLC in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2019–FY2024

+140.4%

+19.17% a year

Each share's claim on the business

−58.4%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $84.2M

over 6 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

No 13F manager reports holding ADAPY.

Super Investors

Investment managers reporting ADAPY on Form 13F

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
RA Rhumbline Advisers	—	—	SOLD OUT		—	0.0%
Shares held by quarter Peak holding19.7K (Q4'24) Change over 8 quarters−19.2K Rhumbline Advisers's full portfolio →

Rhumbline Advisers

—

% of company

—

Change vs last qtr

SOLD OUT

Held since

—

Institutional Funds

Mutual funds and ETFs reporting ADAPY on Form N-PORT; together they hold 0.0% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
FN Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust	$3.95K	67.0K	0.00%	0.00%	August 31, 2025
SC Small Cap Core Fund Northern Funds	$439	16.9K	0.00%	0.00%	December 31, 2025

Fidelity Nasdaq Composite Index Fund

Fidelity Concord Street Trust

Position value

$3.95K

% of company

0.00%

% of the fund

0.00%

As of

August 31, 2025

Small Cap Core Fund

Northern Funds

Position value

$439

% of company

0.00%

% of the fund

0.00%

As of

December 31, 2025

4 more funds behind a free account

See every fund holding Adaptimmune Therapeutics PLC and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
NE New Enterprise Associates 14, L.P. 5%+ holder 13D · 0.0%	4	0.00%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company0.000% Disclosed stake13D · 0.0% View the 13D/G filing →
NP NEA Partners 14, L.P. 5%+ holder 13D · 0.0%	4	0.00%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company0.000% Disclosed stake13D · 0.0% View the 13D/G filing →

New Enterprise Associates 14, L.P.

5%+ holder13D · 0.0%

% of company

0.00%

Change vs last qtr

—

Held since

—

NEA Partners 14, L.P.

5%+ holder13D · 0.0%

% of company

0.00%

Change vs last qtr

—

Held since

—

9 more holders behind a free account

See every insider and 5%+ holder of Adaptimmune Therapeutics PLC.

Comments